An international controlled clinical study published in The New England Journal of Medicine demonstrates that liquid biopsy can help identify…
en_news
While cutaneous melanoma accounts for 1–2% of all skin cancers, it is responsible for the majority of skin cancer deaths…
Reported at the European Society for Medical Oncology (ESMO) Congress 2025 in Berlin, Germany, results from four multicenter early phase…
Results from sub-study 03A of KEYMAKER-U03, an international, open-label, rolling-arm, phase I/II umbrella trial, spotlight the promise of pembrolizumab-based…
Results from the multicenter, open-label, randomized phase 3 DESTINY Breast11 trial show that neoadjuvant antibody-drug conjugate trastuzumab deruxtecan improved pathological…
Results from the LITESPARK-015 open-label, multicohort phase 2 trial show that hypoxia-inducible factor-2 alpha inhibitor belzutifan achieves durable antitumor activity…
The results of the international phase 3 MATTERHORN clinical trial show that adding the antibody durvalumab, an immune checkpoint inhibitor,…
On 27 September, the iconic Paseíco de la Mama took place in Zaragoza. This charity initiative has supported the VHIO…
With the start of the new school year, we are launching a new edition of Escola i Ciència, VHIO’s longest-running…
On September 26, the European Researchers’ Night was celebrated across hundreds of cities in Europe. Once again, VHIO joined the…
